Comment from Lipodystrophy United

Summary: Lipodystrophy United, a patient-led nonprofit organization, supports the Haystack Project petition to modernize FDA drug development frameworks for rare and ultra-rare diseases. They argue that traditional frequentist statistical models are unsuitable for small, heterogeneous patient populations and advocate for the adoption of Bayesian adaptive designs, synthetic control arms, and subtype-specific endpoints.